Yamanouchi Pharmaceutical Company Ltd.

Astellas Pharma Gmbh

Satoshi Hayashibe

Masamichi Okada

Shingo Yamasaki

Nobuyuki Shiraishi

Hiroaki Hoshii

Hirotsune Itahana

Takashi Toya

Daisuke Suzuki

Takashi Kamikubo

Shuichi Sakamoto

Kunihiro Niigata

Takayuki Suzuki

Kenji Negoro

Tatsuya Maruyama

Toshihiro Watanabe

Shin-ichi Tsukamoto

Takatoshi Kanayama

Jiro Fujiyasu

Kazushi Watanabe

Toshiyuki Takasu

Takahiko Tobe

Kyoichi Maeno

Kazuhito Tanabe

Mitsuo Fujii

Takenori Kimura

Junya Ohmori

Atsuyuki Kohara

Itsuro Shimada

Kiyoshi Yahiro

Yukinori Nagakura

Tetsuo Kiso

Hisataka Shikama

Eiko Hirasaki

Masako Umeda

Shin-ichi Yatsugi

Tokio Yamaguchi

To provide a compound which is useful as an NMDA receptor antagonist. The present inventors have studied a compound having an NMDA receptor antagonistic action, and confirmed that the fused indane compound of the present invention has an excellent NMDA receptor antagonistic action, thereby completed the present invention. The fused indane compound of the present invention has an excellent NMDA receptor antagonistic action and can be used as a prophylactic and/or therapeutic agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, intractable depression, attention deficit hyperactivity disorder, migraines, or the like.

Fused indane compound

Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3 -dihydro-1-benzofuran, 2,3-dihydro-1-benzothiophene, indoline ring, or the like, and has Rand R(the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.

Aminoindane derivative or salt thereof

This invention relates to the provision of novel aminomethyl-substituted thiazolobenzimidazole derivatives represented by the following general formula (I) or a salt thereof. The aforementioned derivative or a salt thereof has a metabotropic glutamate receptor action and excellent oral activity and is therefore useful as a medicament. (In the formula, R: an oxygen-containing saturated hetero ring or the like, Alk: a lower alkylene, m: 0 or 1, Alk: a lower alkylene which may be substituted with oxo group, n: 0 or 1, X: a bond, O, S or NR, R: H or the like, and R, R, R, Rand R: the same or different from one another and each represents H or the like. Provided that Rdoes not represent a lower alkyl or a halogeno-lower alkyl when X is a bond and n is 1. Also, Rrepresents a group other than Me when m is 1, Ris OH or OMe and Alkis a Calkylene, and further 1) when X is a bond, n is 1 and Ris H, or 2) when X is a bond, n is 0 and Ris cyclohexane.)

Aminomethyl-substituted thiazolobenzimidazole compounds

This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.

Pharmaceuticals for neurogenic pain

Thiazolobenzoimidazole derivatives

Morpholine derivative

A Maillard reaction inhibitor containing, as an active ingredient, an amidinoheterocyclic derivative or its pharmaceutically acceptable salt, which is useful for the prevention and/or cure of various complications of diabetes and maturity-onset disorders. The amidinoheterocyclic derivatives are also useful as Maillard reaction inhibitors for cosmetics, external endermic medicines, foods, drinks, luxury grocery items and functional foods.

Pyrazole derivatives and compositions and methods of use as maillard

Growing community of inventors

Tokyo, Japan

Satoshi Hayashibe